1. A mass screening has been conducted on newborns for adrenogenital syndrome, galactosemia and cystic fibrosis.

2. The programme of neonatal screening for cystic fibrosis, galactosemia, adrenogenital syndrome and congenital bradyacuasia has been expanded.

3. In people with galactokinase deficiency, a form of galactosemia, excess dulcitol forms in the lens of the eye leading to cataracts.

4. Standardized techniques have been developed for studying infant and maternal mortality, the health of children with adrenogenital syndrome and galactosemia in institutions specialized in genetic and endocrinal illnesses, and the state of health of young persons subject to military registration and conscription.

5. The significance of the lowering of the pH, e.g., in local inflammation (iritis, cyclitis, retinitis, etc.) or general acidoses (diabetes mellitus, galactosemia, hunger, extracorporeal circulation for atrophic kidney. Albright-, Love-, Fanconisyndrome) for the appearance of incipient subcapsular clouding of the lens is pointed out.

6. Also disclosed is a method for treatment, amelioration or prophylaxis of a disease selected from the group consisting of phenylketonuria (PKU, Følling's disease), hyperphenylalaninemia (HPA), alcaptonuria (black urine disease), tyrosinemia, hypertyrosinemia, myasthenia gravis, histidinemia, urocanic aciduria, maple syrup urine disease (MSUD), isovaleric acidemia (isovaleryl-CoA dehydrogenase deficiency), homocystinuria, propionic acidemia, methylmalonic acidemia, and glutaric aciduria Type 1 (GA-I), galactosemia, comprising administering to the gastrointestinal tract of a patient in need thereof an effective amount of a composition of molecular imprinted polymers (MIPs), said composition being capable of binding a symptom provoking agent of said disease.